Table 2 Characteristics of patients with and without ocular involvement.
| Characteristics | Ocular involvement (n = 24) | No ocular involvement (n = 726) | p (2‐tail) |
|---|---|---|---|
| Gender (F:M) | 1.9:1 | 2.3:1 | ns |
| Age at onset (years, months) | <0.05 | ||
| Mean | 5,5 | 7,4 | |
| Median | 4,2 | 7,0 | |
| Range | 0,2–14,3 | 0–16,0 | |
| JLS subtypes (%) | |||
| ECDS | 16 (66.7) | 97 (13.4) | <0.001 |
| Linear | 5 (20.8) | 373 (51.4) | <0.05 |
| Plaque | 1 (4.2) | 121 (26.3) | <0.05 |
| Generalised | 2 (8.3) | 49 (6.7) | ns |
| Deep | 0 (0.0) | 16 (2.2) | ns |
| Extraocular involvement (%) | |||
| Overall | 11 (45.8) | 157 (21.6) | <0.01 |
| Cardiac | 1 (4.2) | 1 (0.1) | ns |
| Neurological | 6 (25) | 28 (3.9) | <0.005 |
| Osteoarticular | 2 (8.3) | 88 (12.1) | ns |
| Respiratory | 1 (4.2) | 4 (0.5) | ns |
| Vascular | 1 (4.2) | 17 (2.3) | ns |
| Autoantibodies | |||
| ANA positive/tested (%) | 12/24 (50.2) | 272/648 (42.0) | ns |
| RF positive/tested (%) | 2/10 (20.0) | 65/398 (16.3) | ns |
| ACL positive/tested (%) | 0/5 (0.0) | 14/114 (12.3) | ns |